Google’s Atlas of the human genome could pave the way for new treatments
THE SO WHAT
If AlphaGenome Atlas works as described, the constraint in genomics shifts from measuring variants to deciding which predicted effects to pursue. Drug discovery orgs should be revisiting their target triage and validation processes now, assuming variant effect prediction becomes a cheap commodity input.
READ THE SOURCE
MORE FROM THE WIRE
Applied AIGoogle and Accenture are putting 1,000 engineers inside client offices
1,000 Google–Accenture engineers embedded on-site is a clear admission that AI value is bottlenecked by integration, not model quality. If you’re buying AI platforms without a forward-deployed engineering plan — internal or partner — you should downgrade your ROI expectations.
Applied AIOpenAI just anchored an Australian company’s Malaysian data centres
OpenAI anchoring 900 MW of Malaysian data centers via an Australian developer is a template for AI-era cross-border infra deals — capital, chips, and offtake all decoupled from location. If you’re planning large-scale AI workloads, you now have to think like an energy-intensive industrial: power, jurisdiction, and anchor contracts matter as much as cloud logos.
Applied AIOracle’s stock gets a boost as the OpenAI ecosystem comes back into favor
Oracle’s rally on “OpenAI ecosystem” sentiment underscores how tightly hyperscale cloud valuations are now coupled to a few anchor model providers. If your infra roadmap is tied to one model ecosystem, you’re effectively making a macro bet on that vendor’s execution and regulatory path.
Applied AIAI ROI to Drive Capex Spending: Dudley
If investors are already pushing AI ROI timelines out while still justifying heavy capex, the market is treating AI infra like long-duration industrial buildout, not quick-payback IT. Operators should separate “must-have” infra bets from speculative ones and be explicit about payback horizons with boards and investors.